CytoMed Therapeutics Limited
GDTC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -82.1% | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 100.7% | 131.4% | – | 96.9% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $1 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | $0 | $0 | -$0 |
| Operating Expenses | $2 | $2 | $2 | $1 |
| Operating Income | -$3 | -$3 | -$2 | -$1 |
| % Margin | -5,049.8% | -1,101% | – | -1,661.4% |
| Other Income/Exp. Net | $1 | $0 | -$1 | -$0 |
| Pre-Tax Income | -$2 | -$3 | -$2 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$3 | -$2 | -$2 |
| % Margin | -3,621.1% | -1,077.8% | – | -1,822.3% |
| EPS | -0.16 | -0.29 | -0.3 | -0.22 |
| % Growth | 44.8% | 3.3% | -36.4% | – |
| EPS Diluted | -0.16 | -0.29 | -0.3 | -0.22 |
| Weighted Avg Shares Out | 12 | 11 | 8 | 7 |
| Weighted Avg Shares Out Dil | 12 | 11 | 8 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$3 | -$1 | -$1 |
| % Margin | -3,443% | -1,011.1% | – | -1,244.7% |